A Systematic Review of the Clinical and Cost-Effectiveness of Memantine in Patients with Moderately Severe to Severe Alzheimer???s Disease
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 23 (3) , 227-240
- https://doi.org/10.2165/00002512-200623030-00005
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- MemantinePharmacoEconomics, 2005
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Cost Effectiveness of Memantine in???Moderately Severe to Severe Alzheimer???s DiseaseClinical Drug Investigation, 2004
- Cost Effectiveness of Memantine in Alzheimer???s DiseaseDrugs & Aging, 2004
- PNM10 COST EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATELY SEVERE AND SEVERE ALZHEIMER'S DISEASE IN SPAINValue in Health, 2003
- A new approach to the qualitative evaluation of functional disability in dementiaInternational Journal of Geriatric Psychiatry, 2003
- Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or olderJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer??s DiseasePharmacoEconomics, 2003
- The Cost of Dementia in Denmark: The Odense StudyDementia and Geriatric Cognitive Disorders, 1999
- Estimating Long Term Cost Savings from Treatment of Alzheimer??s DiseasePharmacoEconomics, 1999